Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2021 Feb 16;10(4):e020289.
doi: 10.1161/JAHA.120.020289. Epub 2021 Feb 6.

Paclitaxel-Coated Devices: Safety and Efficacy Are in the PVI of the Beholder

Douglas E Drachman  1 , Joseph M Garasic  1
Affiliations
Editorial

Paclitaxel-Coated Devices: Safety and Efficacy Are in the PVI of the Beholder

Douglas E Drachman et al. J Am Heart Assoc. .
No abstract available

Keywords: Editorials; drug‐eluting balloon; drug‐eluting stent; paclitaxel; peripheral artery disease; peripheral vascular disease.

PubMed Disclaimer

Conflict of interest statement

Dr Drachman reports personal fees from Abbott Vascular, personal fees from Boston Scientific, personal fees from Broadview Ventures, personal fees from Cardiovascular Systems Inc, and personal fees from Cordis/Cardinal Health, outside the submitted work. Dr Garasic reports personal fees from ACI Clinical, personal fees from Bayer, personal fees from AbbVie, personal fees from Abbott, personal fees from Takeda, personal fees from Siemens, personal fees from Baim Institute, personal fees from Beaufort LLC, personal fees from Parexel, personal fees from Boehringer Ingelheim, other from Ostial Corporation, and other from Vertex Pharmaceuticals, outside the submitted work.

Comment on

References

    1. Dake MD, Ansel GM, Jaff MR, Ohki T, Saxon RR, Smouse HB, Machan LS, Snyder SA, O’Leary EE, Ragheb AO, et al. Durable clinical effectiveness with paclitaxel‐eluting stents in the femoropopliteal artery: 5‐year results of the Zilver PTX randomized trial. Circulation. 2016;133:1472–1483.DOI: 10.1161/CIRCULATIONAHA.115.016900. - DOI - PMC - PubMed
    1. Schneider PA, Laird JR, Tepe G, Brodmann M, Zeller T, Scheinert D, Metzger C, Micari A, Sachar R, Jaff MR, et al. Treatment effect of drug‐coated balloons is durable to 3 years in the femoropopliteal arteries: long‐term results of the IN.PACT SFA randomized trial. Circ Cardiovasc Interv. 2018;11:e005891. - PMC - PubMed
    1. Klein AJ, Jaff MR, Gray BH, Aronow HD, Bersin RM, Diaz‐Sandoval LJ, Dieter RS, Drachman DE, Feldman DN, Gigliotti OS, et al. SCAI appropriate use criteria for peripheral arterial interventions: an update. Catheter Cardiovasc Interv. 2017;90:E90–E110.DOI: 10.1002/ccd.27141. - DOI - PubMed
    1. Bailey SR, Beckman JA, Dao TD, Misra S, Sobieszczyk PS, White CJ, Wann LS, Bailey SR, Dao T, Aronow HD, et al. ACC/AHA/SCAI/SIR/SVM 2018 appropriate use criteria for peripheral artery intervention: a report of the American College of Cardiology Appropriate Use Criteria Task Force, American Heart Association, Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol. 2019;73:214–237. - PMC - PubMed
    1. Katsanos K, Spiliopoulos S, Kitrou P, Krokidis M, Karnabatidis D. Risk of death following application of paclitaxel‐coated balloons and stents in the femoropopliteal artery of the leg: a systematic review and meta‐analysis of randomized controlled trials. J Am Heart Assoc. 2018;7:e011245. DOI: 10.1161/JAHA.118.011245. - DOI - PMC - PubMed

MeSH terms

LinkOut - more resources